- Previous Close
64.26 - Open
65.70 - Bid 65.60 x 700
- Ask 65.67 x 700
- Day's Range
65.57 - 66.46 - 52 Week Range
60.47 - 87.68 - Volume
6,321,308 - Avg. Volume
5,360,123 - Market Cap (intraday)
203.493B - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
31.71 - EPS (TTM)
2.07 - Earnings Date Feb 6, 2025
- Forward Dividend & Yield 1.49 (2.26%)
- Ex-Dividend Date Aug 9, 2024
- 1y Target Est
88.27
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZN
View More
Performance Overview: AZN
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZN
View MoreValuation Measures
Market Cap
204.33B
Enterprise Value
230.96B
Trailing P/E
31.63
Forward P/E
14.01
PEG Ratio (5yr expected)
0.71
Price/Sales (ttm)
4.01
Price/Book (mrq)
5.00
Enterprise Value/Revenue
4.51
Enterprise Value/EBITDA
15.53
Financial Highlights
Profitability and Income Statement
Profit Margin
12.68%
Return on Assets (ttm)
8.50%
Return on Equity (ttm)
16.66%
Revenue (ttm)
51.21B
Net Income Avi to Common (ttm)
6.5B
Diluted EPS (ttm)
2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
4.93B
Total Debt/Equity (mrq)
77.47%
Levered Free Cash Flow (ttm)
9.51B
Research Analysis: AZN
View MoreCompany Insights: AZN
AZN does not have Company Insights
Research Reports: AZN
View MoreTrump’s Nomination of RFK Jr. to Lead HHS a Potential Industry Headwind
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
RatingPrice TargetAstraZeneca Earnings: In-Line Results; Dato-DXd Repositioned; Fair Value Estimate Unchanged
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
RatingPrice TargetBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
RatingPrice TargetAstraZeneca Holds a Strong Portfolio and Pipeline That Support Solid Long-Term Growth
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
RatingPrice Target